Milestone Pharma Q3 net loss widens on commercial expenses

Reuters11-12

Milestone Pharma Q3 net loss widens on commercial expenses

Overview

Milestone Q3 2025 reports no revenue, net loss of $11.9 mln
Company prepares for CARDAMYST launch pending FDA approval in December
Milestone strengthens finances with equity offering and royalty agreement

Outlook

Milestone plans quick launch of CARDAMYST following potential FDA approval
Company expects $75 mln royalty payment upon CARDAMYST FDA approval
Milestone poised to enter Phase 3 program for etripamil in AFib-RVR

Result Drivers

COMMERCIAL EXPENSES - Increased to support pre-launch activities for CARDAMYST nasal spray
FINANCIAL PREPARATION - Equity offering and amended royalty agreement provide resources for CARDAMYST launch
CLINICAL DATA - Etripamil shows consistent efficacy and safety in clinical trials for PSVT

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Basic EPS		-$0.12
Q3 Income From Operations		-$11.83 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Milestone Pharmaceuticals Inc is $4.00, about 52.3% above its November 11 closing price of $1.91

Press Release: ID:nGNX9WQQF4

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582375915?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582375915","market":"us","top_or_hot":-1,"title":"Milestone Pharma Q3 net loss widens on commercial expenses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Milestone Pharma Q3 net loss widens on commercial expenses </title></head><body><p><span>Overview</span></p><ul><li><p>Milestone Q3 2025 reports no revenue, net loss of $11.9 mln</p></li><li><p>Company prepares for CARDAMYST launch pending FDA approval in December</p></li><li><p>Milestone strengthens finances with equity offering and royalty agreement</p></li></ul><p><span>Outlook</span></p><ul><li><p>Milestone plans quick launch of CARDAMYST following potential FDA approval</p></li><li><p>Company expects $75 mln royalty payment upon CARDAMYST FDA approval</p></li><li><p>Milestone poised to enter Phase 3 program for etripamil in AFib-RVR</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COMMERCIAL EXPENSES - Increased to support pre-launch activities for CARDAMYST nasal spray</p></li><li><p>FINANCIAL PREPARATION - Equity offering and amended royalty agreement provide resources for CARDAMYST launch</p></li><li><p>CLINICAL DATA - Etripamil shows consistent efficacy and safety in clinical trials for PSVT</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.12</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$11.83 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Milestone Pharmaceuticals Inc is $4.00, about 52.3% above its November 11 closing price of $1.91</p></li></ul><p>Press Release: <span>ID:nGNX9WQQF4</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Milestone Pharma Q3 net loss widens on commercial expenses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMilestone Pharma Q3 net loss widens on commercial expenses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Milestone Pharma Q3 net loss widens on commercial expenses </title></head><body><p><span>Overview</span></p><ul><li><p>Milestone Q3 2025 reports no revenue, net loss of $11.9 mln</p></li><li><p>Company prepares for CARDAMYST launch pending FDA approval in December</p></li><li><p>Milestone strengthens finances with equity offering and royalty agreement</p></li></ul><p><span>Outlook</span></p><ul><li><p>Milestone plans quick launch of CARDAMYST following potential FDA approval</p></li><li><p>Company expects $75 mln royalty payment upon CARDAMYST FDA approval</p></li><li><p>Milestone poised to enter Phase 3 program for etripamil in AFib-RVR</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COMMERCIAL EXPENSES - Increased to support pre-launch activities for CARDAMYST nasal spray</p></li><li><p>FINANCIAL PREPARATION - Equity offering and amended royalty agreement provide resources for CARDAMYST launch</p></li><li><p>CLINICAL DATA - Etripamil shows consistent efficacy and safety in clinical trials for PSVT</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.12</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$11.83 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Milestone Pharmaceuticals Inc is $4.00, about 52.3% above its November 11 closing price of $1.91</p></li></ul><p>Press Release: <span>ID:nGNX9WQQF4</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0DG:1","article_id":"2582375915","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582375915","pubTimestamp":1762949820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Milestone Pharma Q3 net loss widens on commercial expensesOverviewMilestone Q3 2025 reports no revenue, net loss of $11.9 mlnCompany prepares for CARDAMYST launch pending FDA approval in DecemberMiles","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","MIST":"Milestone Pharmaceuticals Inc."},"translate_title":"Milestone Pharma第三季度商业费用净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIST":0.9},"content_text":"Milestone Pharma Q3 net loss widens on commercial expenses OverviewMilestone Q3 2025 reports no revenue, net loss of $11.9 mlnCompany prepares for CARDAMYST launch pending FDA approval in DecemberMilestone strengthens finances with equity offering and royalty agreementOutlookMilestone plans quick launch of CARDAMYST following potential FDA approvalCompany expects $75 mln royalty payment upon CARDAMYST FDA approvalMilestone poised to enter Phase 3 program for etripamil in AFib-RVRResult DriversCOMMERCIAL EXPENSES - Increased to support pre-launch activities for CARDAMYST nasal sprayFINANCIAL PREPARATION - Equity offering and amended royalty agreement provide resources for CARDAMYST launchCLINICAL DATA - Etripamil shows consistent efficacy and safety in clinical trials for PSVTKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Basic EPS-$0.12Q3 Income From Operations-$11.83 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"Wall Street's median 12-month price target for Milestone Pharmaceuticals Inc is $4.00, about 52.3% above its November 11 closing price of $1.91Press Release: ID:nGNX9WQQF4For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582375915","isCrawlerRequest":true}